

REBYOTA- donor human stool suspension

Ferring Pharmaceuticals Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use REBYOTA safely and effectively. See full prescribing information for REBYOTA.

REBYOTA™ (fecal microbiota, live - jslm) suspension, for rectal use
Initial U.S. Approval: 2022

INDICATIONS AND USAGE

REBYOTA is indicated for the prevention of recurrence of *Clostridioides difficile* infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. (1)

Limitation of Use:

REBYOTA is not indicated for treatment of CDI.

DOSAGE AND ADMINISTRATION

For rectal administration only.

Administer REBYOTA 24 to 72 hours after the last dose of antibiotics for CDI. (2)

Administer a single dose of 150 mL rectally of REBYOTA. (2)

DOSAGE FORMS AND STRENGTHS

Suspension. A single dose is 150 mL. (3)

CONTRAINDICATIONS

Severe allergic reactions (e.g. anaphylaxis) to any component of REBYOTA. (4)

ADVERSE REACTIONS

The most commonly reported ($\geq 3\%$) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%) (Table 1).

To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dose

2.2 Preparation

2.3 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Transmissible infectious agents

5.2 Management of acute allergic reactions

5.3 Potential presence of food allergens

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action

13 NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

REBYOTA is indicated for the prevention of recurrence of *Clostridioides difficile* infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.

Limitation of Use:

REBYOTA is not indicated for treatment of CDI.

2 DOSAGE AND ADMINISTRATION

For rectal administration only.

2.1 Dose

A single dose is 150 mL.


2.2 Preparation

Prior to use, thaw REBYOTA completely by placing the carton in a refrigerator, 2°C to 8°C (36°F to 46°F), for approximately 24 hours. REBYOTA carton may be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and used within 5 days, including thawing time.


DO NOT thaw using a heat source such as a microwave or hot water.

Condensation is normal after thawing.


Remove the thawed REBYOTA carton from the refrigerator. Remove the bag containing thawed REBYOTA from the outer carton and the inner carton insert. DO NOT remove the bag containing thawed REBYOTA from the sealed outer bag. Locate an Administration Set (supplied), water-soluble lubricant (not included) and a disposable underpad (not included) (See Figure 1).



1. Open the administration set and close the pinch clamp by pushing the clamp until it is fully closed (see Figure 2).



2. Remove the tab from the spike port of the bag containing thawed REBYOTA and remove the cap from the administration tube spike. Insert the administration tube spike through the spike port of the bag containing thawed REBYOTA (see Figure 3).




DO NOT remove air from the administration tube prior to insertion to avoid loss of REBYOTA.

2.3 Administration


Administer REBYOTA 24 to 72 hours after the last dose of antibiotics for CDI.

1. Prepare the patient for administration by requesting they empty their bladder and


bowel, if possible. Place the patient in the left-side position or the knee-chest position with a disposable underpad beneath the patient (see Figures 4 and 5).



OR



2. Apply water-soluble lubricant to the administration tube tip. Gently insert the administration tube tip into the rectum about 12 cm (5 inches) in a direction pointed slightly toward the navel (umbilicus) (see Figure 6).




3. Hold the administration tube in place with one hand for the entire procedure to maintain the tube position in the rectum. With the other hand, open the pinch clamp on the administration tube, and then gradually raise the bag to allow delivery of REBYOTA via gravity flow (see Figure 7 and 8).


DO NOT allow the administration tube to sag or loop as this will prevent the entire dose from being delivered.

DO NOT squeeze the bag to deliver REBYOTA as this could be uncomfortable for the patient.

DO NOT hang the bag from an IV stand.




OR




4. When the entire dose has been delivered, close the pinch clamp and then slowly withdraw the tube. Take care to prevent any residual REBYOTA remaining in the tube from leaking out.

NOTE: Some REBYOTA will remain in the tube after administration.

5. Keep the patient in the left-side position or the knee-chest position for up to 15 minutes to minimize any cramping that may occur (see Figure 9 and 10). There are no restrictions on the patient's use of the restroom.



OR



Dispose of all components in medical waste.

3 DOSAGE FORMS AND STRENGTHS

Suspension. A single dose is 150 mL.

4 CONTRAINDICATIONS

Do not administer REBYOTA to individuals with a history of a severe allergic reaction (e.g. anaphylaxis) to any of the known product components [see Description 11].

5 WARNINGS AND PRECAUTIONS

5.1 Transmissible infectious agents

Because REBYOTA is manufactured from human fecal matter it may carry a risk of transmitting infectious agents. Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Ferring Pharmaceuticals Inc.

5.2 Management of acute allergic reactions

Appropriate medical treatment must be immediately available in the event an acute anaphylactic reaction occurs following administration of REBYOTA.

5.3 Potential presence of food allergens

REBYOTA is manufactured from human fecal matter and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown.

6 ADVERSE REACTIONS

The most commonly reported ($\geq 3\%$) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of REBYOTA was evaluated in 2 randomized, double-blind clinical studies (Study 1: NCT03244644 and Study 2: NCT02299570) and 3 open-label clinical studies (NCT01925417, NCT02589847, NCT03931941) conducted in the United States and Canada. A total of 978 adults 18 years of age and older with a history of 1 or more recurrences of *Clostridioides difficile* (CDI) infection and whose symptoms were controlled 24 – 72 hours post-antibiotic treatment were enrolled and received 1 or more doses of REBYOTA; 595 of whom received a single dose of REBYOTA. In the 2 randomized, double-blind clinical studies, 131 adults were originally randomized to receive placebo and 48 crossed over to receive an open-label dose of REBYOTA after additional CDI recurrence. Overall, across the 5 studies, the median age of participants was 64 years and 67.2 % were female. The racial and ethnic distribution was as follows: 93.8% were white, and 2.4% were of Hispanic or Latino ethnicity. No meaningful differences in demographic characteristics occurred across the treatment groups. Study 1 and Study 2 excluded individuals with celiac disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, and chronic diarrhea. Individuals with these conditions were not excluded from one of the open-label studies (NCT03931941), and individuals with food allergies were not excluded from any of the 5 clinical studies.

Adverse Reactions

Across the 5 clinical studies, participants recorded solicited adverse events in a diary for the first 7 days after each dose of REBYOTA or placebo. Participants were monitored for all other adverse events by queries during scheduled visits, with duration of follow-up ranging from 6 to 24 months after the last dose. In Study 1, a multi-center, double-blind

randomized (2:1), placebo-controlled trial conducted in the United States and Canada, 180 adults 18 years of age and older received a single dose of REBYOTA and 87 received placebo. Participants with a recurrence of CDI (rCDI) during the first 8 weeks after receipt of REBYOTA or placebo were censored from analysis at the time of rCDI. During the first two weeks following a dose of REBYOTA or placebo, 34 participants (18.9%) and 24 participants (27.6%) respectively, were censored. Overall, during the 8 week follow up period, 47 REBYOTA recipients (26.1%) and 30 placebo recipients (34.5%) were censored from analysis. In an analysis of solicited and unsolicited adverse events reported in Study 1, the most common adverse reactions (defined as adverse events assessed as definitely, possibly, or probably related to Investigational Product by the investigator) reported by $\geq 3\%$ of REBYOTA recipients, and at a rate greater than that reported by placebo recipients, were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%) (Table 1).

Table 1: Adverse Reactions* reported by $\geq 3\%$ of REBYOTA recipients, and at a rate greater than that reported by placebo recipients, within 8 weeks after receipt of REBYOTA or placebo (Study 1).

Adverse Reaction	REBYOTA N=180 n (%)	Placebo N=87 n (%)
Abdominal Pain	16 (8.9)	6 (6.9)
Diarrhea	13 (7.2)	3 (3.4)
Abdominal distension	7 (3.9)	2 (2.3)
Flatulence	6 (3.3)	0
Nausea	6 (3.3)	1 (1.1)

* Adverse reactions were defined as solicited and unsolicited adverse events that were assessed as definitely, possibly or probably related to treatment by the study investigator.

Most adverse reactions occurred during the first 2 weeks after treatment. After this, the proportion of patients with adverse reactions declined in subsequent 2-week intervals. Beyond 2 weeks after treatment only a few single adverse reactions were reported. Most adverse drug reactions were mild to moderate in severity. No life-threatening adverse reaction was reported.

Serious Adverse Reactions

In a pooled analysis of the 5 clinical studies, 10.1% (60/595) of REBYOTA recipients (1 dose only) and 7.2% (6/83) of placebo recipients reported a serious adverse event within 6 months post last dose of investigational product. None of these events were considered related to the investigational product.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

REBYOTA is not absorbed systemically following rectal administration, and maternal use is not expected to result in fetal exposure to the drug.

8.2 Lactation

REBYOTA is not absorbed systemically by the mother following rectal administration, and breastfeeding is not expected to result in exposure of the child to REBYOTA.

8.4 Pediatric Use

Safety and effectiveness of REBYOTA in individuals younger than 18 years of age have not been established.

8.5 Geriatric Use

Of the 978 adults who received REBYOTA, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of REBYOTA are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.

11 DESCRIPTION

REBYOTA (fecal microbiota, live – js1m) is an opaque fecal microbiota suspension for rectal administration. REBYOTA is manufactured from human fecal matter sourced from qualified donors. The human fecal matter is tested for a panel of transmissible pathogens. Donors do not have dietary restrictions with respect to potential food allergens. The fecal microbiota suspension is the filtrate generated by processing the fecal matter in a pre-defined ratio with a solution of polyethylene glycol (PEG) 3350 and saline. Each 150mL dose of REBYOTA contains between 1×10^8 and 5×10^{10} colony forming units (CFU) per mL of fecal microbes including $>1 \times 10^5$ CFU/mL of *Bacteroides*, and contains not greater than 5.97 grams of PEG3350 in saline.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of REBYOTA has not been established.

13 NONCLINICAL TOXICOLOGY

No nonclinical toxicology studies were conducted.

14 CLINICAL STUDIES

The effectiveness of REBYOTA was evaluated using a Bayesian analysis of data from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study (Study 1), which formally integrated treatment success rates from a placebo-controlled Phase 2 study (Study 2). Enrolled adults in both studies were 18 years of age or older and had a

confirmed diagnosis of recurrent CDI (one or more episodes in Study 1; two or more episodes in Study 2) which was defined as diarrhea (passage of 3 or more loose bowel movements within a 24-hour period for 2 consecutive days) and a positive stool test for *C. difficile* toxin or toxigenic *C. difficile*, or had at least two episodes of severe CDI resulting in hospitalization within the last year. Enrolled adults were required to have completed at least 10 consecutive days of antibiotic therapy and have their CDI under control (<3 unformed/loose, i.e., Bristol Stool Scale type 6-7, stools/day for 2 consecutive days). A minimum of 24 hours to a maximum of 72 hours (Study 1) or 24 hours to a maximum of 48 hours (Study 2) antibiotic washout period was required prior to administration of the assigned study treatment. In Study 1, enrolled adults were randomized 2:1 to a single dose of REBYOTA or placebo respectively. In Study 2, randomization was 1:1:1 to receive two doses of REBYOTA, two doses of placebo, or one dose of REBYOTA and one dose of placebo, administered 7±2 days apart. Only data from the REBYOTA one-dose group and the placebo group are described below and were integrated in the Bayesian analysis.

In the integrated efficacy analysis set, the demographic profile and baseline recurrent CDI characteristics of treated adults were similar in the REBYOTA and placebo groups. In Study 1, a total of 262 adults were randomized and treated, of which 177 adults received REBYOTA and 85 received placebo. Adults had a mean age of 60.1 years with 45.4% of adults 65 years of age or older, were mainly white (92.0%) and female (69.1%). In this study, 32.8% of adults received REBYOTA or placebo for their first recurrence of CDI. In Study 1, 87.4% of adults had received vancomycin alone prior to treatment. In Study 2, 39 adults received one dose of REBYOTA and one dose of placebo and 43 adults received two doses of placebo. Adults in these two groups had a mean age of 59.8 years with 42.7% of adults 65 years of age or older, were mainly white (97.6%) and female (63.4%). In this study, 89.0% of adults had received vancomycin prior to treatment.

Treatment success was defined as the absence of CDI diarrhea within 8 weeks of blinded treatment. CDI diarrhea was defined as the passage of ≥ 3 unformed/loose stools in ≤ 24 hours for at least 2 consecutive days and a positive stool test for the presence of *C difficile* toxin at the time of the diarrhea.

In the Bayesian analysis, the estimated rate of treatment success was significantly higher in the REBYOTA group (70.6%) than in the Placebo group (57.5%) through 8 weeks after completing blinded treatment, resulting in a difference of 13.1 percentage points (95% Credible Interval: 2.3, 24.0) which corresponds to a 99.1% posterior probability that REBYOTA is superior to Placebo (Table 2).

Table 2: Efficacy Results: Treatment Success at 8 weeks Post-Treatment (mITT Population*)

Parameter	REBYOTA Mean (95% CrI)	Placebo Mean (95% CrI)	Treatment Effect (REBYOTA - Placebo) Mean (95% CrI)
Model-Estimated	70.6	57.5	13.1

Treatment Success (%)	(64.1, 76.8)	(48.1, 67.1)	(2.3, 24.0)
Posterior Probability of Superiority	-	-	0.991 [†]

Cri=credible interval

* mITT includes all randomized subjects excluding: 1) those who withdrew prior to treatment; 2) those in whom treatment was attempted but not completed; 3) those who discontinued from the study prior to evaluation of treatment outcome for the primary endpoint if the reason for exit was not related to CDI symptoms.

† Pre-defined threshold was 0.975

Study 1 evaluated sustained clinical response which was defined as treatment success at 8 weeks and no CDI event through 6 months after the last dose during the blinded period. The difference in sustained clinical response rate (9.1%; 95% CI: -3.6%, 21.7%) was not statistically significant between the REBYOTA (65.5%) and the placebo groups (56.5%).

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

REBYOTA and the administration set are shipped together in a box. Each box may contain up to 6 cartons of REBYOTA and up to 6 administration sets. Each carton of REBYOTA (NDC 55566-9800-2) contains a single dose.

16.2 Storage and Handling

REBYOTA contains live microorganisms. It is important to follow the storage requirements.

Upon Receipt:

Store the REBYOTA carton in an ultracold freezer (-60°C to -90°C, -76°F to -130°F). Alternatively, store in a refrigerator (2°C to 8°C, 36°F to 46°F) for up to 5 days (including thaw time). Do not refreeze REBYOTA after thawing.

Store the administration set at 10°C to 34°C (50°F to 93°F). DO NOT store the administration set in the freezer.

Before Using:

Prior to use, thaw REBYOTA completely by placing carton in a refrigerator (2°C to 8°C, 36°F to 46°F) for approximately 24 hours. Do not refreeze REBYOTA after thawing.

Dispose of all components in medical waste.

17 PATIENT COUNSELING INFORMATION

Inform patients that REBYOTA is manufactured from human fecal matter and may contain food allergens.

Inform patients to notify their physician if persistent diarrhea, defined as 3 or more loose bowel movements within a 24-hour period for 2 consecutive days, returns following REBYOTA administration.

Patients should not take any oral antibiotic therapy for up to 8 weeks after administration of REBYOTA unless directed by their physician.

Manufactured for Ferring Pharmaceuticals
by Rebiotix, Inc. Roseville, MN 55113

US License No. 2112

Ferring, the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
REBYOTA is a trademark of Ferring B.V.

9009000002

PRINCIPAL DISPLAY PANEL - 150 mL Bag Carton

FERRING
PHARMACEUTICALS

NDC 55566-9800-2

1 single-dose
Rx Only

fecal microbiota, live-*jsIm*
REBYOTA™

For rectal administration only.

Store and thaw in this carton.

Store the REBYOTA carton in an ultracold freezer (-60°C to -90°C, -76°F to -130°F). Alternatively, store in a refrigerator (2°C to 8°C, 36°F to 46°F) for up to 5 days (including thaw time). Do not refreeze REBYOTA after thawing.

Before Using:


Prior to use, thaw REBYOTA completely by placing carton in a refrigerator (2°C to 8°C, 36°F to 46°F) for approximately 24 hours. Do not refreeze REBYOTA after thawing.

Condensation is normal
after thawing.

Contents:

One inner carton containing
a suspension bag of a single
150 mL dose of REBYOTA.

Use with the Administration Set
provided in a separate carton.



REBYOTA

donor human stool suspension

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:55566-9800
Route of Administration	RECTAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
Donor Human Stool (UNII: 3TVP4E28JR) (Donor Human Stool - UNII:3TVP4E28JR)	Donor Human Stool	50000000000 [CFU] in 150 mL

Packaging

#	Item Code	Package Description	Marketing Start	Marketing End
---	-----------	---------------------	-----------------	---------------

#	Item Code	Package Description	Date	Date
1	NDC:55566-9800-2	1 in 1 CARTON	01/09/2023	
1	NDC:55566-9800-1	1 in 1 CARTON		
1	NDC:55566-9800-0	150 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125739	01/09/2023	

Labeler - Ferring Pharmaceuticals Inc. (103722955)

Revised: 12/2024

Ferring Pharmaceuticals Inc.